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Urinary tract infection (UTI) is a common complication in patients with urolithiasis. This
study aimed to compare clinical manifestations and treatment outcomes among UTI
patients with or without urolithiasis. It also focused on identifying relationships among
urolithiasis, uroseptic shock, and acute kidney injury (AKI). This retrospective study
enrolled hospitalized UTI patients who underwent imaging in an acute care setting from
January 2006 to March 2015. Of 662 participants enrolled, 113 (17.1%) had urolithiasis,
107 (16.2%) developed uroseptic shock, and 184 (27.8%) developed AKI. A multivariate
logistic regression analysis showed that in UTI patients, urolithiasis is associated with an
increased risk of uroseptic shock (OR 1.80, 95% CI: 1.08–3.02, P = 0.025), AKI (OR
1.95, 95% CI: 1.22–3.12, P = 0.005), and bacteremia (OR 1.68, 95% CI: 1.08–2.64, P
= 0.022). Urolithiasis is common in UTI patients and is associated with an increased risk
of uroseptic shock and AKI.
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INTRODUCTION
Urolithiasis is a global problem with an increasing incidence and prevalence rate (1, 2). The global
prevalence of urolithiasis ranges from 2 to 20% and varies based on geographical locations and
socioeconomic conditions of different populations (3, 4). Urolithiasis is a well-known risk factor of
urinary tract infection (UTI), and a vicious cycle leading to several clinical consequences is observed
seen as follows: stones → obstruction → stasis → infection → stones (5). Furthermore,
urolithiasis is associated with an increased risk of chronic kidney disease (CKD), hypertension,
and myocardial infarction (6–8).
Urolithiasis can lead to urinary stasis, which enables bacteria to adhere to the urothelium and
multiply, thereby causing UTI (9). Complicated UTI related to obstructive uropathy can progress to
urosepsis and may cause septic shock and disseminated intravascular coagulopathy (10). However,
only a few studies have demonstrated the correlation among urolithiasis, uroseptic shock, and
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acute kidney injury (AKI) in UTI patients. Hence, we conducted
a study to investigate whether urolithiasis is an important risk
factor for uroseptic shock and AKI in UTI patients.
MATERIALS AND METHODS
Study Design and Patient Selection
The data for this retrospective observational study were collected
between January 2006 and March 2015 from patients visiting
Chiayi Christian Hospital in southern Taiwan, which consists
of 1,077 inpatient beds and an outpatient department serving
∼4,110 patients per day. This study was conducted after
obtaining ethical approval from the Institutional Review Board
of Chiayi Christian Hospital (approval no. CYCH-IRB-100015).
In total, 662 consecutively hospitalized UTI patients without
any other concurrent infectious disease were enrolled in the
study. All patients were adults and presented with UTI symptoms
such as pain on urination, lumbago, or fever with bacterial
isolation of >105 colony-forming units/mL from a urine
specimen. All patients underwent imaging studies, such as
ultrasonography, intravenous urography (IVU), or computed
tomography (CT), to identify urolithiasis and urinary tract
obstruction. The patients were divided into two groups based on
the presence or absence of urolithiasis. The clinical characteristics
and laboratory data were collected using a standard form for
further analysis.
Assessment of the Subjects
Data on demographic characteristics (age and sex), comorbidities
[diabetes mellitus (DM), hypertension, coronary artery disease,
congestive heart failure (CHF), stroke, and long-term indwelling
Foley catheter], vital signs (blood pressure and temperature),
laboratory results [white blood cell (WBC) count, platelet count,
serum creatinine, and estimated glomerular filtration rate (eGFR)
at baseline and after hospitalization], causative microorganisms
and antimicrobial resistance pattern, and imaging of patients
were collected and analyzed.
Definitions
The diagnosis of urolithiasis was based on imaging studies.
Urolithiasis was defined as the presence of any stone formation
in the urinary tract that was detected during imaging studies
such as ultrasonography, CT with or without enhancement, or
IVU. Uroseptic shock was defined as sepsis-induced hypotension
[systolic blood pressure (SBP) <90 mmHg or mean arterial
pressure <70 mmHg or a decrease in SBP by >40 mmHg and
lasting for at least 1 h, despite adequate fluid resuscitation and
in the absence of other causes of hypotension] (11). eGFR was
determined using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) creatinine equation (12, 13). For
patients without recognized CKD, the estimation of baseline
creatinine level was performed using the CKD-EPI creatinine
equation assuming a GFR of 75 ml/min/1.73 m2 (14). AKI was
defined as an increase in serum creatinine level to ≥1.5 times
the baseline values according to the KDIGO Clinical Practice
Guideline criteria for serum creatinine value for AKI stages 1, 2,
and 3 (15). Afebrile status was defined as a body temperature of
≤38.3◦C (101◦F) during hospitalization.Multiple drug resistance
(MDR) was defined as non-susceptibility of the isolates to at least
one agent in three or more antimicrobial categories (16).
Statistical Analyses
The patients were grouped into two categories: those with or
without urolithiasis. The continuous variables were expressed
as mean ± SD, and the categorical variables were expressed as
number (percentage). The data were analyzed using Student’s
t-test or chi-square test depending on the type of variables.
Multivariate logistic regression analyses were performed to
identify factors associated with urolithiasis, septic shock, and AKI
post-admission. Only variables significant at the 0.15 level in
the univariate analysis were selected for consecutive multivariate
analyses. The goodness-of-fit of the logistic regression model was
assessed using the Cox and Snell test, and the explanatory power
was reported using Nagelkerke’s pseudo-R-square. A P-value of
<0.05 was considered statistically significant. All analyses were
performed using SPSS software for Windows (SPSS Science, v.
17.0, Chicago, IL).
RESULTS
The demographic and clinical characteristics of 662 hospitalized
UTI patients are shown in Table 1. The mean age on admission
was 67 ± 17 years. A majority of the patients [468 (70.7%)]
were females, and 229 (34.6%) had a prior history of UTI.
There were 107 patients (16.2%) with uroseptic shock and 184
patients (27.8%) with AKI during hospitalization. The overall
mortality rate was 0.45% (3/662). Among UTI patients, 113
(17.1%) had urolithiasis and 41 had ureteral stone with urinary
tract obstruction. The ureteral stones were located at the upper
ureter or ureteropelvic junction in 18 patients (43.9%), mid ureter
in 5 (12.2%), and distal ureter and ureterovesical junction in
18 (43.9%). Thirty (16.3%) and 81 patients (16.9%) underwent
radiologic examinations using contrast media (IVU or CT) in
the AKI and non-AKI groups, respectively. The prevalence of
male sex (40.7 vs. 27.0%, P = 0.003), bacteremia (57.5 vs. 40.3%,
P = 0.001), uroseptic shock (26.5 vs. 14.0%, P = 0.001), AKI
(40.7 vs. 25.1%, P = 0.001) and Proteus spp. isolates (10.6 vs.
2.6%, P < 0.001) was higher, while Escherichia coli isolates (61.1
vs. 75.8%, P = 0.002) was lower in patients with urolithiasis
than in those without. Among UTI patients with urolithiasis, the
incidences of AKI were 60.0 and 33.7%, respectively, in patients
with and without uroseptic shock. The top five bacteria identified
in UTI patients with urolithiasis were E. coli (61.1%), Proteus spp.
(10.6%), Klebsiella spp. (8.8%), Pseudomonas spp. (8.0%), and
Enterococcus spp. (3.5%). The top five bacteria identified in UTI
patients without urolithiasis were E. coli (75.8%), Klebsiella spp.
(7.7%), Pseudomonas spp. (7.1%), Enterococcus spp. (4.6%), and
Proteus spp. (2.6%).
CHF (OR 2.43, 95% CI: 1.03–5.77, P = 0.043), urolithiasis
(OR 1.80, 95% CI: 1.08–3.02, P = 0.025), and AKI (OR 2.30,
95% CI: 1.45–3.65, P < 0.001) were independently associated
with an increased risk of uroseptic shock (Table 2). Patients
with DM (OR 1.78, 95% CI: 1.21–2.60, P = 0.003), afebrile
during hospitalization (OR 1.63, 95% CI: 1.08–2.44, P = 0.019),
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TABLE 1 | Characteristics of hospitalized patients with urinary tract infection with respect to urolithiasis.
All (n = 662) Non-urolithiasis (n = 549) Urolithiasis (n = 113) P-value
Age (year) 67 ± 17 67 ± 18 67 ± 15 0.603*
Sex (male) 194 (29.3) 148 (27.0) 46 (40.7) 0.003U
Diabetes mellitus 282 (42.6) 232 (42.3) 50 (44.2) 0.697U
Hypertension 335 (50.6) 275 (50.1) 60 (53.1) 0.561U
Congestive heart failure 28 (4.2) 23 (4.2) 5 (4.4) 0.802U
Coronary artery disease 64 (9.7) 55 (10.0) 9 (8.0) 0.501U
Stroke 157 (23.7) 134 (24.4) 23 (20.4) 0.356U
Prior history of UTI 0.726U
None 433 (65.4) 357 (65.0) 76 (67.3)
Once 123 (18.6) 105 (19.1) 18 (15.9)
Twice 59 (8.9) 50 (9.1) 9 (8.0)
Thrice or more 47 (7.1) 37 (6.7) 10 (8.8)
Indwelling Foley catheter 58 (8.8) 46 (8.4) 12 (10.6) 0.443U
Afebrile 270 (40.8) 231 (42.1) 39 (34.5) 0.136U
Bacteremia 286 (43.2) 221 (40.3) 65 (57.5) 0.001U
Uroseptic shock 107 (16.2) 77 (14.0) 30 (26.5) 0.001U
Acute kidney injury 184 (27.8) 138 (25.1) 46 (40.7) 0.001U
Acute kidney injury stage 0.004U
Stage 1 99 (15.0) 78 (14.2) 21 (18.6)
Stage 2 58 (8.8) 41 (7.5) 17 (15.0)
Stage 3 27 (4.1) 19 (3.5) 8 (7.1)
Baseline serum creatinine (mg/dL) 1.1 ± 0.8 1.1 ± 0.8 1.1 ± 0.8 0.665*
Baseline eGFR (mL/min/1.73 m2) 70.5 ± 28.7 70.4 ± 29.7 71.2 ± 23.6 0.755*
Hospitalized serum creatinine (mg/dL) 1.6 ± 1.4 1.6 ± 1.4 1.7 ± 1.4 0.561*
Hospitalized eGFR (mL/min/1.73 m2 ) 58.2 ± 36.4 56.0 ± 32.2 50.9 ± 27.1 0.076*
White blood cell (103/µL) 13.4 ± 6.1 13.4 ± 5.9 13.7 ± 7.3 0.649*
Platelets (103/µL) 207 ± 124 209 ± 130 202 ± 92 0.600*
Escherichia coli 485 (73.3) 416 (75.8) 69 (61.1) 0.002U
Proteus species 26 (3.9) 14 (2.6) 12 (10.6) <0.001U
Klebsiella species 52 (7.9) 42 (7.7) 10 (8.8) 0.811U
Enterococcus species 29 (4.4) 25 (4.6) 4 (3.5) 0.803U
Pseudomonas species 48 (7.3) 39 (7.1) 9 (8.0) 0.903U
MDR isolate 234 (35.3) 190 (34.6) 44 (38.9) 0.381U
*Student’s t-test; UChi-square test or Fisher’s exact test.
Data are expressed as mean ± SD or number (percentage).
MDR, multiple drug resistance; eGFR, estimated glomerular filtration rate.
bacteremia (OR 2.19, 95% CI: 1.47–3.26, P < 0.001), uroseptic
shock (OR 2.44, 95% CI: 1.51–3.93, P < 0.001), urolithiasis (OR
1.95, 95% CI: 1.22–3.12, P = 0.005), and higher WBC count
(OR 1.04, 95% CI: 1.00–1.07, P = 0.025) were independently
associated with an increased risk of AKI. Conversely, higher
eGFR (OR 0.99, 95%CI: 0.98–0.99, P< 0.001) was independently
associated with a decreased risk of AKI in UTI patients (Table 3).
Figure 1 shows a reduction in eGFR in UTI patients with
uroseptic shock and urolithiasis. The reduction in eGFR values
in uroseptic shock patients with or without urolithiasis, and UTI
patients with or without urolithiasis were 28.35 (95% CI: 19.23–
37.46), 20.78 (95% CI: 16.58–24.97), 17.05 (95%CI: 13.72–20.39),
and 13.28 (95% CI: 12.05–14.50) mL/min/1.73 m2, respectively.
Significant differences were observed between uroseptic shock
patients with urolithiasis and UTI patients with urolithiasis,
uroseptic shock patients without urolithiasis and UTI patients
without urolithiasis, uroseptic patients with urolithiasis and UTI
patients without urolithiasis, and UTI patients with urolithiasis
and UTI patients without urolithiasis. Urolithiasis (OR 1.68, 95%
CI: 1.08–2.64, P = 0.022), AKI (OR 1.87, 95% CI: 1.26–2.78, P
= 0.002), and higher WBC count (OR 1.04, 95% CI: 1.01–1.07, P
= 0.006) were independently associated with an increased risk of
bacteremia, while afebrile status (OR 0.32, 95% CI: 0.22–0.46, P
< 0.001) and higher platelet count (OR 1.00, 95% CI: 0.99–1.00,
P < 0.001) were independently associated with a decreased risk
of bacteremia in UTI patients (Table 4).
DISCUSSION
The relationship between urolithiasis and UTI is complex.
UTI is a common complication in patients with urolithiasis,
and it promotes the formation of urolithiasis (5). Our study
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TABLE 2 | Univariate and multivariate logistic regression analyses of factors related to uroseptic shock in patients with urinary tract infection.
Covariate Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age (year) 1.01 (1.00–1.03) 0.038 1.01 (0.99–1.02) 0.230
Sex (male) 1.48 (0.96–2.29) 0.077 1.49 (0.94–2.37) 0.093
Diabetes mellitus 0.93 (0.61–1.42) 0.736
Hypertension 0.83 (0.55–1.26) 0.382
Congestive heart failure 3.08 (1.38–6.86) 0.006 2.43 (1.03–5.77) 0.043
Coronary artery disease 2.04 (1.12–3.71) 0.019 1.54 (0.80–2.94) 0.195
Stroke 1.31 (0.82–2.09) 0.252
Indwelling Foley catheter 0.95 (0.45–1.99) 0.889
Afebrile 0.66 (0.43–1.03) 0.065 0.62 (0.38–1.02) 0.060
Bacteremia 1.95 (1.28–2.96) 0.002 1.34 (0.84–2.15) 0.216
Acute kidney injury 2.76 (1.80–4.22) <0.001 2.30 (1.45–3.65) <0.001
Urolithiasis 2.22 (1.37–3.59) 0.001 1.80 (1.08–3.02) 0.025
Baseline eGFR (mL/min/1.73 m2) 1.00 (0.99–1.00) 0.292
White blood cell (103/µL) 1.02 (0.99–1.06) 0.157
Platelets (103/µL) 1.00 (1.00–1.00) 0.024 1.00 (1.00–1.00) 0.166
eGFR, estimated glomerular filtration rate.
TABLE 3 | Univariate and multivariate logistic regression analyses of factors related to acute kidney injury in patients with urinary tract infection.
Covariate Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age (year) 1.03 (1.02–1.04) <0.001 1.01 (0.99–1.03) 0.206
Sex (male) 0.80 (0.55–1.18) 0.260
Diabetes mellitus 2.19 (1.55–3.10) <0.001 1.78 (1.21–2.60) 0.003
Hypertension 1.95 (1.38–2.77) <0.001 1.30 (0.87–1.95) 0.197
Congestive heart failure 2.73 (1.27–5.84) 0.010 1.84 (0.78–4.32) 0.161
Coronary artery disease 1.77 (1.04–3.02) 0.036 1.13 (0.62–2.05) 0.698
Stroke 1.02 (0.68–1.51) 0.941
Indwelling Foley catheter 0.99 (0.54–1.81) 0.970
Afebrile 1.45 (1.03–2.04) 0.035 1.63 (1.08–2.44) 0.019
Bacteremia 2.11 (1.50–2.99) <0.001 2.19 (1.47–3.26) <0.001
Uroseptic shock 2.76 (1.80–4.22) <0.001 2.44 (1.51–3.93) <0.001
Urolithiasis 2.04 (1.34–3.12) 0.001 1.95 (1.22–3.12) 0.005
Baseline eGFR (mL/min/1.73 m2) 0.98 (0.98–0.99) <0.001 0.99 (0.98–0.99) <0.001
White blood cell (103/µL) 1.04 (1.01–1.07) 0.004 1.04 (1.00–1.07) 0.025
Platelets (103/µL) 1.00 (1.00–1.00) 0.568
eGFR, estimated glomerular filtration rate.
demonstrated a higher prevalence of urolithiasis in UTI patients
than in the general population. The presence of urolithiasis
was associated with worse clinical outcomes in UTI patients,
including an increased risk of bacteremia, uroseptic shock, and
AKI. To the best of our knowledge, this is the first study to
demonstrate that urolithiasis is associated with an increased risk
of uroseptic shock and AKI in UTI patients.
Patients with septic shock are in a critical situation that
requires significant healthcare resources. It is estimated that
UTI is the underlying cause in 30% of patients with severe
sepsis and septic shock (17). The rate of developing septic shock
in patients with UTI can range from 20.8 to 32.9% based on
different underlying conditions (18–20). In the current study, the
incidence of uroseptic shock in UTI patients that necessitated
admission was 16.2%. Multiple factors attributing to septic shock
have previously been reported in patients with UTI. Indwelling
urinary catheter and increased C-reactive protein levels were
risk factors of septic shock in UTI patients with or without
bacteremia (18, 21). Our study showed that urolithiasis could
be a good predictor of the development of uroseptic shock in
UTI patients. Previous studies showed that the rate of uroseptic
shock in calculous acute pyelonephritis (APN) ranged from
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20.8 to 36.2% (22, 23). Here, we found a similar incidence
(26.5%) of uroseptic shock in UTI patients with urolithiasis. UTI
with urinary tract obstruction can lead to urosepsis in ∼10%
of cases (24), and the presence of urinary tract obstruction
is a risk factor for septic shock in patients with bacteremic
APN (19, 25). A lack of decompression leads to an increased
risk of mortality for patients with sepsis and ureteral stone
(26). It is important to decompress the renal collecting system
by ureteral stent or pyelonephrostomy for UTI patients with
severe urinary tract obstruction (27). Because urolithiasis is an
independent risk factor for the development of septic shock
in UTI patients, early imaging for sepsis patients with clinical
suspicion of urinary source and decompressing the urinary
collecting system for those with obstruction is recommended. For
patients identifying severe sepsis or septic shock, administration
of effective intravenous antibiotics within an hour is critical
according to the recommendation of Surviving Sepsis Campaign
guidelines (11).
The primary mechanism of urolithiasis-associated AKI is
obstructive nephropathy (28). However, urolithiasis is a rare
cause of adult AKI, accounting for ∼1–2% of all AKI events
only (28). One of the common causes of AKI in critically ill
patients is sepsis (29), and ∼60% of patients with septic shock
develop AKI (30). Urolithiasis is a risk factor for UTI, and
UTI is one of the common causes of sepsis, which may lead to
uroseptic shock and deterioration of renal function. Our study
found a high incidence of AKI (46.7%) among the patients
with uroseptic shock, and uroseptic shock was an independent
risk factor for AKI. UTI patients with urolithiasis were more
prone to develop uroseptic shock and tended to have a greater
reduction in eGFR than those without urolithiasis, regardless of
the presence of uroseptic shock. Because patients with urolithiasis
or uroseptic shock are both predisposed to develop more
severe AKI, nephrotoxic agents, including non-steroidal anti-
inflammatory drugs, contrast media, and aminoglycosides should
be avoided in patients with a high risk of AKI.
The presence of bacteremia in complicated APN patients
results in an increased risk of developing severe sepsis or
uroseptic shock (31). Previous studies have indicated that specific
clinical features in UTI patients, such as old age, low SBP,
high body temperature, and high procalcitonin levels, were
significantly associated with bacteremia (32). Our study showed
that UTI patients with urolithiasis, AKI, and higher WBC count
were at a higher risk of developing bacteremia. Urolithiasis
per se is an important source of secondary infection (33). A
previous study reported that the incidence of bacteria isolated
from urine and stone matrices of stone formers was 24 and
32%, respectively (34). Traditionally, UTI with urease-producing
bacteria, in most cases belonging to Proteus spp., can split
urinary urea and increase urinary pH, thus, promoting the
precipitation and aggregation of struvite crystals to form infective
urolithiasis (5). However, UTIs are frequently associated with
kidney stones of different chemical compositions other than
struvite (34). Tavichakorntrakool et al. reported that the three
most common bacteria in urine samples of patients with renal
stones were E. coli, Enterococcus spp., and Klebsiella/Enterobacter
spp. (34). Our data showed that the three most common
FIGURE 1 | eGFR reduction in UTI patients with respect to uroseptic shock
and urolithiasis. eGFR, estimated glomerular filtration rate; UTI, urinary tract
infection; eGFR reduction, baseline minus worst value of eGFR. *p < 0.05,
**p < 0.01.
pathogens in UTI patients with urolithiasis were E. coli,
Proteus spp., and Klebsiella spp. There were more isolates of
Proteus spp. but fewer isolates of E. coli in UTI patients with
urolithiasis than in those without urolithiasis. Third-generation
cephalosporin is a reasonable empirical antibiotic for stable
community-acquired UTI associated with urolithiasis, while
broader spectrum antimicrobial coverage is needed for patients
with severe sepsis or septic shock (18). In addition, urolithiasis
contains bacteria, and the number of bacteria on the stone surface
can increase despite antibiotic therapy. Thus, eradication of the
associated UTI is only possible after complete removal of the
stone (35).
Our study had several limitations. First, the retrospective
design involved a potential bias in data collection. Although we
collected data using a standard form to reduce bias, the data
regarding prior history of urolithiasis, as well as the type and
size of urolithiasis were absent. A prospective study is needed
to collect the above information to determine the associations
between urolithiasis burden and urosepsis, as well as uroseptic
shock and AKI. Second, this was a single-center study involving
hospitalized patients with UTI, which limits the generalizability
of the results. A multicenter study with a larger sample size
will be needed to confirm our results. Third, in this study, the
patient number with urinary tract obstruction was insufficient to
evaluate it as a risk factor for causing uroseptic shock and AKI in
UTI patients with urolithiasis. These limitations will be addressed
in our future study.
In conclusion, we demonstrated that UTI patients with
urolithiasis have a higher risk of developing uroseptic shock and
AKI than those without urolithiasis. Therefore, careful medical
history and imaging studies for urolithiasis are important for
physicians to prevent andmanage acute and severe complications
in UTI patients.
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TABLE 4 | Univariate and multivariate logistic regression analyses of factors related to bacteremia in patients with urinary tract infection.
Covariate Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age (year) 1.00 (0.99–1.01) 0.499
Sex (male) 0.95 (0.68–1.33) 0.755
Diabetes mellitus 1.32 (0.97–1.81) 0.077 1.30 (0.91–1.85) 0.146
Hypertension 1.26 (0.92–1.71) 0.146 1.41 (0.99–2.00) 0.059
Congestive heart failure 0.99 (0.46–2.12) 0.970
Coronary artery disease 1.18 (0.70–1.98) 0.533
Stroke 0.66 (0.46–0.96) 0.030 0.70 (0.46–1.06) 0.088
Indwelling Foley catheter 0.73 (0.42–1.27) 0.262
Afebrile 0.34 (0.24–0.47) <0.001 0.32 (0.22–0.46) <0.001
Uroseptic shock 1.95 (1.28–2.96) 0.002 1.42 (0.89–2.26) 0.138
Acute kidney injury 2.11 (1.50–2.99) <0.001 1.87 (1.26–2.78) 0.002
Urolithiasis 2.01 (1.33–3.03) 0.001 1.68 (1.08–2.64) 0.022
Baseline eGFR (mL/min/1.73 m2) 1.00 (0.99–1.00) 0.519
White blood cell (103/µL) 1.03 (1.01–1.06) 0.017 1.04 (1.01–1.07) 0.006
Platelets (103/µL) 1.00 (1.00–1.00) <0.001 1.00 (0.99–1.00) <0.001
eGFR, estimated glomerular filtration rate.
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